In the case of a very inflammatory and itchy form of scaly erythroderma or ILC, a biotherapy blocking IL-17A (such as Secukinumab or Ixekizumab) appears to be currently the best therapeutic option to improve the permanent inflammatory condition of the skin and/or to prevent acute flares. This evidence concerns the gene IL17A and exfoliative dermatitis.